Abstracts included drug cost and the reduced compliance of medication by methylphenidate users (61%) versus AMP/DEX users (86%) and the AMP/DEX response rate. CONCLUSIONS: Generic Adderall TM is the dominant strategy over generic Ritalin TM given that compliance and side effect rates are consistently higher for generic Adderall TM . However, it is difficult to make strong generalizations about cost-effectiveness between therapies given the overlapping efficacy rates and similar side effect profiles of competing treatments as reported in the literature. Clinicians should find it appropriate to initiate stimulants in the short term regardless of the specific agent available.
included drug cost and the reduced compliance of medication by methylphenidate users (61%) versus AMP/DEX users (86%) and the AMP/DEX response rate. CONCLUSIONS: Generic Adderall TM is the dominant strategy over generic Ritalin TM given that compliance and side effect rates are consistently higher for generic Adderall TM . However, it is difficult to make strong generalizations about cost-effectiveness between therapies given the overlapping efficacy rates and similar side effect profiles of competing treatments as reported in the literature. Clinicians should find it appropriate to initiate stimulants in the short term regardless of the specific agent available. 7 University Psychiatric Clinic, "Papageorgiou" General Hospital, Athens, Greece; 8 University of Ioannina, Ioannina, Greece OBJECTIVES: Evaluation of schizophrenic patients requires measurements that extend, beyond mere estimation of psychopathology symptoms, to assessment of quality of life levels. The relationship between psychopathology and HRQOL changes has not been extensively studied. The objective of this study is to assess correlations between psychopathology (Positive and Negative Symptom Scale, PANSS) and a disease-specific questionnaire, the Quality of Life Scale (QLS), in the evaluation of schizophrenia patients. METHODS: An open-label, 52-week follow-up study of 170 patients is being conducted in 8 Greek public psychiatric hospitals. Patients with mild to moderate schizophrenia (according to DSM-IV criteria) aged 18-65, hospitalized or outpatients, newly diagnosed or in acute exacerbation were enrolled. Psychopathology was assessed by PANSS general psychopathology, positive and negative symptom scores. HRQOL was assessed by QLS total and 4 subscale scores (interpersonal relationships, instrumental role, intrapsychic foundations and common objects and activities). Correlations analysis was used to identify the relationship between PANSS and QLS scores at baseline and at stabilization after 6-months treatment. Six month follow-up data are presented in this analysis. RESULTS: At baseline, a weak but statistically significant (p < 0.001) association was found between the 4 QLS subscale scores and PANSS general and negative symptom scores. Correlation coefficients ranged from r = -0.18 (p < 0.05) (QLS instrumental role vs. PANSS negative) to r = -0.46 (p < 0.001) (QLS intrapsychic foundation vs. PANSS negative). At six months a stronger and statistically significant association was observed. Correlation coefficients ranged from r = -0.32 (p < 0.001) (QLS total score vs. PANSS general) to r = -0.56 (p < 0.001) (QLS intrapsychic foundation vs. PANSS negative). CONCLUSIONS: The study reveals a statistically significant correlation between PANSS and QLS at baseline scores, which is improved over the 6-months follow-up period. HRQL measures and psychopathology seem to change synchronically; the correlation is enhanced as the control of schizophrenia symptoms is improved.
PMH42 CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY

PMH43 DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONS
Ascher-Svanum H, Zhu B, Faries D, Jiang Q, Kinon BJ Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Antipsychotics differ in their impact on prolactin, and sustained elevation in prolactin levels is associated with sexual dysfunction. Unlike risperidone, olanzapine is known as a prolactin-sparing antipsychotic. This study aimed to: a) compare olanzapine and risperidone on reported sexual dysfunction during the long-term treatment of schizophrenia patients in usual care, and b) examine the associations between sexual dysfunction, medication adherence, and indicators of well-being for all patients. METHOD: Data of the U.S. Schizophrenia Care and Assessment Program (SCAP), a 3-year observational study of schizophrenia patients, were used to identify participants who were treated with olanzapine (N = 330) or risperidone (N = 216) at enrollment and continued on the drug for a minimum of 1 year. The SCAP-Health Questionnaire was used to measure patients' self-reported medication-related sexual dysfunction at 6-month intervals. Group differences on changes in sexual dysfunction levels from baseline up to 3 years were examined using a mixed model with repeated measures (MMRM). Pearson correlations examined the associations between sexual dysfunction, medication adherence and indicators of well-being. RESULTS: Compared to risperidone-treated patients, those treated with olanzapine reported significantly greater long-term improvements in medication-related sexual dysfunction (p < 0.001). Greater sexual dysfunction was significantly (p < 0.05) associated with greater emotional distress, poorer mental functioning, lower life satisfaction, less satisfaction with social life, and poorer self-reported medication adherence. CONCLUSION: Treatment with risperidone was associated with greater sexual dysfunction compared to olanzapine. Findings suggest that minimizing treatment-related sexual dysfunction may decrease emotional distress, improve life satisfaction, and increase adherence with medication. This study examined whether remission of psychotic symptoms is associated with favorable long-term functional and health-related quality of life (HRQOL) outcomes in the treatment of schizophrenia patients in usual care. METHODS: We used data from the United States Schizophrenia Care and Assessment Program (SCAP), a 3-year observational study of schizophrenia, in which participants were assessed at enrollment and 12-month intervals. Remission of psychotic symptoms was defined using the Remission in Schizophrenia Working Group expert consensus criteria. Functional and HRQOL outcomes were assessed with validated measures. Four patient groups were compared on long-term outcomes: continuously remitted patients (R AE R, N = 229); continuously nonremitted patients (NR AE NR, N = 1110); patients who changed from non-remitted to remitted and stayed remitted (NR AE R, N = 234); and patients who changed from remitted to nonremitted and stayed non-remitted (R AE NR, N = 202). Analysis employed Generalized Estimating Equation (GEE) and mixed models with repeated-measures. RESULTS: The R AE R group had significantly better outcomes than the NR AE NR and R AE NR groups on measures of productivity and occupational functioning, social activity, daily activity, Global Assessment of Functioning (GAF), mental health, quality of life, and life satisfaction. The NR AE R group did not significantly differ from the R AE R group on most measures, but had significantly poorer quality of life, daily activity, GAF, and occupational functioning. CON-CLUSIONS: In this large prospective naturalistic study, remission of psychotic symptoms was associated with a broad range of favorable long-term functional and HRQOL outcomes. Findings highlight the importance of achieving and maintaining symptomatic remission in the long-term treatment of schizophrenia patients in usual practice settings. University Centrum V.Z.W, Centrum, Belgium OBJECTIVES: To explore the feasibility of estimating a preference based utility score for the SQLS-R4 by mapping it onto the utility scores generated from the published SF-6D and EQ-5D tariffs. METHODS: The study consisted of a sample of 156 people with schizophrenia who completed the SQLS-R4, EQ-5D and the SF-36. To facilitate regression modelling both sets of scores were subtracted from unity to give utility decrement on the scale zero to positive infinite. In the regression models the utility decrements were entered as dependent variables with the three levels of SQLS-R4 data [total score, domain scores, individual items scores] acting as explanatory variables. For each of the levels two models were considered each for the EQ-5D and SF-6D, the standard OLS model and a gamma distribution GLM with the canonical log link. RESULTS: For both the EQ-5D and SF-6D models as the number of explanatory variables increased so did the variance explained by the data (R2), with a gradual steady increase for the SF-6D, compared to a much sharper increase from 43% to 55% for the EQ-5D. AICs were used to provide a comparison between the OLS models and the GLMs. For all 3 levels of SQLS-R4 explanatory variables the GLM (gamma/log) was preferred over the OLS model for the EQ-5D data, with the opposite being true for the SF-6D. CONCLU-SIONS: There was little to choose between the 3 levels of models, with the exception that much more variance was accounted for by inclusion of all the items compared to the domain scores for the EQ-5D OLS model. However, caution should be taken when selecting which model to use, as the EQ-5D GLM model resulted in higher utility scores than the SF-6D OLS model for patients with good quality of life, whereas the opposite was true for patients with poor quality of life.
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